ACR-368 - In OncoSignature-positive endometrial cancer subjects, the Objective Response Rate (ORR) with ACR-368 single agent is 39% (n=31)[31] - In subjects with ≤ 2 prior lines of therapy, the ORR in BM+ subjects is 44% (n=25) and in BM- subjects is 26% (n=35) with ACR-368 single agent and ACR-368 + ULDG combo, respectively[34] - In BM+ subjects with ≤ 2 prior lines, the ORR in serous carcinosarcoma is 67% (n=12)[37] - In biomarker-unselected subjects with ≤ 2 prior lines, the ORR in serous subjects is 52% (n=23) and in non-serous subjects is 22% (n=37)[40] - In serous subjects with ≤ 2 prior lines, the Disease Control Rate (DCR) is 92% and Clinical Benefit Rate (CBR) at 16 weeks is 83% in Arm 1 (BM+), while in Arm 2 (BM-) the DCR is 55% and CBR at 16 weeks is 45%[43] - Serous endometrial cancer accounts for approximately 40% of all endometrial cancer deaths, equating to roughly 20,000 deaths per year in the US and EU[46, 52] ACR-2316 - In the Phase 1 dose escalation study, clinical activity was observed at dose level 120 mg and above, with tumor shrinkage in 9 out of 20 evaluable patients[74] - A total of 33 patients were dosed across two weekly dosing schedules in the ongoing Phase 1 monotherapy dose-escalation study[68, 74] - In the Phase 1 study, 79% of the subjects were White, 9% were Black/African American, 3% were Asian, 3% were Native Hawaiian/Pacific Islander, and 6% were Unknown/Other[69] Financials - As of December 31, 2025, Acrivon has approximately $119 million in cash and investments, projecting a runway into Q2 2027[96]